Saturday, March 7, 2026
HomeStock MarketMerck Keytruda variations OK'd in U.S. for bladder most cancers (MRK)

Merck Keytruda variations OK’d in U.S. for bladder most cancers (MRK)


Grandbrothers/iStock Editorial by way of Getty Photographs

The U.S. Meals and Drug Administration (FDA) on Friday authorised injectable and intravenous variations of Merck’s (MRK) blockbuster anti-PD-1 remedy Keytruda for bladder most cancers as a part of a mix routine with Pfizer (PFE) and Astellas’ (OTCPK:ALPMF) (OTCPK:ALPMY) Padcev.

Accordingly, intravenous Keytruda and



Supply hyperlink

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Recent Comments